ACTIMMUNE, Phase 3 clinical study will begin enrolling patients in the second quarter of 2015

ACTIMMUNE, Phase 3 clinical study will begin enrolling patients in the second quarter of 2015. StreetInsider.com, January 12, 2015

It is anticipated that approximately 110 subjects will be screened at four U.S. centers for eligibility to randomize approximately 90 subjects 1:1 to receive either ACTIMMUNE or placebo. The Company anticipates the study will take 18 months to complete.